apremilast / Generic mfg. - LARVOL DELTA

GLP-1 agonist as an adjunct therapy in benign familial chronic pemphigus (Hailey–Hailey disease) (EADV 2026) - "With no definitive cure, treatments include topicals agents (e.g. corticosteroid, antibiotics, 5-fluorouracil, …) and systemic treatments (retinoids, immunosuppressive/immunomodulating drugs, antibiotics, …) as well as laser therapy, photodynamic therapy and surgical treatments...Over the disease course the patient underwent multiple treatments including oral prednisolone, dapsone, methotrexate, adalimumab, omalizumab, apremilast, acitretin, doxycycline, low-dose naltrexone as well as UV-B therapy; however, these therapies were either ineffective or resulted in adverse effects that necessitated discontinuation...As shown in a previous report of a successful treated patient with HDD receiving liraglutide, the decrease of the proinflammatory cytokine IL-6 due to GLP-1 agonists, which has been shown to play an important role in the regulation of ATP2C1 expression in the skin, might have a causal and beneficial effect of the disease...Additionally, GLP-1 agonists, such as..."

Diabetes • Genetic Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Pruritus • Type 2 Diabetes Mellitus • IL6

Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates durable efficacy for up to 60 weeks in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "Materials and Methods Two phase 3 randomized, double-blind, international multicentre trials compared once-daily zasocitinib 30 mg with placebo or twice-daily apremilast 30 mg over 52 (LATITUDE-PsO-3001) or 60 weeks (LATITUDE-PsO-3002). Conclusions Once-daily oral zasocitinib demonstrated durable skin clearance across two pivotal phase 3 trials, with over 90% of patients who continued zasocitinib during the re-randomized withdrawal period in the LATITUDE‑PsO‑3002 study maintaining sPGA 0/1, PASI 75 or PASI 90 response over a ~5-month period. The durability of efficacy responses are being further characterized in a 3-year, open-label, long-term extension study in adults with moderate-to-severe plaque psoriasis (NCT06550076)."

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates superior skin clearance (PASI 100) versus an approved oral TYK2 inhibitor, deucravacitinib, and a consistent safety profile in moderate-to-severe plaque psoriasis: results from a randomized phase 3 intraclass head-to-head trial (LATITUDE Atlas) (EADV 2026) - P3 | "In two pivotal phase 3 placebo- and active- (apremilast) controlled trials in adults with moderate-to-severe plaque psoriasis (LATITUDE-PsO-3001 [NCT06088043] and -3002 [NCT06108544]), zasocitinib demonstrated rapid, durable and reproducible skin clearance with a consistent safety profile. Conclusion In this phase 3 comparative trial, highly selective TYK2 inhibition with oral zasocitinib 30 mg QD showed superior skin clearance with multiple efficacy endpoints (including PASI 100, PASI 90, absolute PASI ≤2 and sPGA 0) versus the TYK2 inhibitor deucravacitinib at Week 16, with higher response rates from Week 8. The overall safety and tolerability profile of zasocitinib was consistent with previous trials."

Clinical • Head-to-Head • Late-breaking abstract • P3 data • Acne Vulgaris • Cardiovascular • Dermatology • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Venous Thromboembolism • TYK2

Once-daily oral zasocitinib, a highly selective TYK2 inhibitor, demonstrates rapid improvements in skin clearance, quality of life and psoriasis symptoms in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "Materials and Methods Two phase 3 randomized, double-blind, international multicentre trials compared once-daily zasocitinib 30mg with placebo or twice-daily apremilast 30mg over 52 (LATITUDE-PsO-3001) or 60 weeks (LATITUDE-PsO-3002). Progressive improvements in PASI 75, sPGA 0/1, PASI 90, PASI 100, sPGA 0, DLQI 0/1, weekly mean PSSD symptom score and PSSD itch response rates were observed through Week 24 following treatment with zasocitinib. Conclusions Once-daily treatment with zasocitinib is associated with rapid skin improvement, improvement in patients' quality of life and reduction of symptoms and signs of disease, including itch, with early response evident within the first four weeks of treatment."

Clinical • HEOR • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

APREM-CU: Apremilast Added to Antihistamines in Chronic Urticaria (clinicaltrials.gov) - P2 | N=86 | Enrolling by invitation | Sponsor: Rashid Latif Medical College

New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 100 in Participants With Moderate-to-Severe Psoriasis and Uncontrolled Psoriatic Arthritis Across All Skin Tones (EADV 2026) - "Prior psoriasis treatments included topicals (76.6%), phototherapy (14.9%), methotrexate (21.3%), apremilast (6.4%), and biologics (any biologic [42.6%]; tumor necrosis factor [21.3%], interleukin [IL-]17 [19.1%], and IL-12/23 [19.1%] inhibitors). In these GUS-treated participants with uncontrolled and often undiagnosed PsA at baseline, mean PsAID-12 scores decreased below the PASS at Week 16, indicating this group achieved clinically meaningful improvements in the physical and psychological impact of joint disease. Improvements continued and were maintained through 100 weeks of treatment."

Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • TNFA

Combinations of targeted therapies relevant for patients with psoriasis and associated immune-mediated diseases: a scoping review (EADV 2026) - "The most reported CTT was an IL23-inhibitor combined with dupilumab...Of the 107 biologic-SMI CTTs, mainly biologic-apremilast combinations, 56.1% were initiated for isolated refractory PsO, and 29.9% for refractory PsO and a concomitant disease...Eight CTTs were a combination of two biologics, mainly a TNFα-inhibitor combined with ustekinumab, and 3 CTTs were a combination of a biologic with a JAK-inhibitor...Across the identified 759 CTTs in diseases sharing targeted therapies with PsO, mostly including vedolizumab for inflammatory bowel disease (IBD), unique SAE rates were also relatively low (6.6%) and seemed to reflect the underlying IBD population...In addition, no alarming safety signals were observed across all identified CTTs. Until more robust evidence on effectiveness and safety of these regimens becomes available, vigilance and monitoring is recommended."

Clinical • Review • Atopic Dermatitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Efficacy and safety of dual targeted therapy using biologics and small molecules for psoriasis and comorbidities: A systematic review (EADV 2026) - "Among 91 patients with only psoriasis, the most commonly reported dual targeted therapies included apremilast with ustekinumab (33.0%, 30/91) and apremilast with secukinumab (8.8%, 20/91). Clinical improvement was observed in 97.8% of patients, with the greatest Psoriasis Area and Severity Index (PASI) reductions achieved by apremilast with infliximab (-96.6%; 24.0 weeks) and apremilast with secukinumab (-91.4%; 29.0 weeks). Among 20 patients with psoriasis and atopic dermatitis, the most common dual targeted therapies included dupilumab with guselkumab (60.0%, 12/20) and dupilumab with risankizumab (20.0%, 4/20)...The greatest reductions in PASI were achieved by dupilumab with risankizumab (-100%; 66.5 weeks) and dupilumab with secukinumab (-80.0%, 40.0 weeks)...These findings highlight the potential of precision combination immunotherapy to address complex immune dysregulation in patients with refractory psoriasis and inflammatory comorbidities. Given the increasing..."

Clinical • Review • Asthma • Atopic Dermatitis • Bullous Pemphigoid • Chronic Spontaneous Urticaria • CNS Disorders • Dermatitis • Dermatology • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Prurigo Nodularis • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Seronegative Spondyloarthropathies • Ulcerative Colitis • Urticaria

Real‑world treatment patterns of oral therapies for psoriasis in Japan (EADV 2026) - "Results A total of 6,019 patients initiating oral therapy were included; treatments were apremilast (56.8%), ciclosporin (24.7%), etretinate (11.4%), methotrexate (6.3%), and deucravacitinib (0.8%). Psoriasis-Related Healthcare Resource Utilization by Persistence Status and Study Period Conclusions In real‑world clinical practice in Japan, persistence with currently available oral therapies for psoriasis was modest, and early treatment discontinuation or modification was associated with higher psoriasis‑related healthcare utilization during treatment and over subsequent follow‑up. These findings highlight limitations of current oral treatments and an unmet need for more effective and safe oral options offering sustained disease control."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Depression • Dermatology • Diabetes • Dyslipidemia • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • TYK2

Cross-regional comparison of dermatologist perceptions of psoriasis treatment, emerging pipeline therapies, and unmet needs in Europe and the United States. (EADV 2026) - "Results Across both regions, the psoriasis treatment landscape is increasingly dominated by IL-23 inhibitors, with risankizumab emerging as the leading biologic, largely at the expense of adalimumab and ustekinumab. In the US, risankizumab leads across all lines of therapy, whereas in the EU5 later-line use remains more distributed, with bimekizumab approaching risankizumab in third-line share (14% vs 15%)...EU physicians anticipate positioning icotrokinra primarily as a second-line therapy, preferred over apremilast and deucravacitinib, with approximately half of dermatologists indicating intent to initiate within the first three months of availability. Additional oral therapies are in late-stage development, with simepdekinra (oral IL-17 inhibitor) ranking second to icotrokinra on interest, likelihood to prescribe, and approval preference across regions...Unmet need for oral therapies is also greater in the US. Across regions, icotrokinra is viewed as the leading..."

Dermatology • Immunology • Psoriasis • IL17A • IL23A

Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates efficacy at high impact sites in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "A greater proportion of patients receiving zasocitinib had hfPGA response at Week 16 (70.7%/69.2%) versus those receiving placebo (22.0%; nominal p <0.001/10.2%; nominal p <0.001) or apremilast (44.4%; nominal p =0.022/42.6%; nominal p <0.001), which continued to Week 24 for zasocitinib (73.7%/70.0%) versus apremilast (22.2%; nominal p <0.001/50.8%; nominal p =0.006) ( Figure C ). Conclusions In adults with moderate-to-severe plaque psoriasis, once-daily oral zasocitinib demonstrates reproducible efficacy at high impact sites including the scalp, nails, palms and soles."

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

Artificial Intelligence and Machine Learning for Prognostic Biomarkers in Psoriatic Disease: A Systematic Review (EADV 2026) - "For treatment response, the IL‑18/IL‑13 ratio predicted secukinumab super‑response (PASI=0 at week 12) with AUC=0.86, while a neural network identified fast responders (PASI75 at week 4) with 92% accuracy. Another study using penalized regression linked a monocyte gene signature to apremilast response at week 16...Future research should focus on prospective clinical trials and the integration of multi-omic datasets. Greater algorithmic transparency will be essential to validate these prognostic tools for routine dermatological practice."

Biomarker • Machine learning • Review • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • CXCL8 • HLA-C • IL13

Zasocitinib, a highly selective once-daily TYK2 inhibitor, demonstrates consistent improvements in quality of life and PSSD-reported symptoms in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "A similar trend was observed in CfB in weekly mean PSSD symptom score up to Week 16 with zasocitinib vs apremilast. Conclusions Once-daily oral zasocitinib demonstrates consistent and meaningful improvements in patient quality of life and signs and symptoms of disease, including itch relief, in adults with moderate-to-severe plaque psoriasis."

Clinical • HEOR • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

Refractory Palmoplantar Psoriasis Successfully Treated With Apremilast After Failure of Multiple Systemic and Biologic Therapies – A Case Report (EADV 2026) - "Previous treatment with methotrexate, acitretin, and cyclosporine had been discontinued due to adverse effects and poor tolerability...The patient subsequently underwent biologic therapy with ixekizumab followed by risankizumab; however, both treatments failed to achieve satisfactory clinical improvement...Failure of sequential biologic therapies does not preclude clinical response to phosphodiesterase-4 inhibition. Our case highlights apremilast as a potentially effective and well-tolerated therapeutic option in difficult-to-treat palmoplantar psoriasis, particularly in patients with inadequate response or intolerance to conventional systemic and biologic therapies."

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis

The Efficacy and Safety of Oral Biologics and Small Molecule Inhibitors for Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis (EADV 2026) - "Introduction Systemic options for moderate-to-severe plaque psoriasis have expanded with the development of oral small molecule inhibitors, including PDE4 inhibitors (apremilast, orismilast, roflumilast), TYK2 inhibitors (deucravacitinib, zasocitinib, envudeucitinib, ropsacitinib), and the first-in-class oral IL-23 receptor inhibitor icotrokinra. Among interventions with a more robust evidence base, icotrokinra 200 mg/day and deucravacitinib 6 mg/day demonstrated substantially greater efficacy than apremilast with comparable safety. Larger head-to-head trials and longer follow-up are needed to confirm the standing of the newer oral treatments."

Retrospective data • Review • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL23A • TYK2

Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, was not associated with clinically meaningful laboratory parameter changes for up to 60 weeks in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "Materials and Methods Two phase 3 randomized, double-blind, international multicentre trials compared once-daily zasocitinib 30 mg with placebo or twice-daily apremilast 30 mg over 52 (LATITUDE-PsO-3001) or 60 weeks (LATITUDE-PsO-3002). There were no cases of rhabdomyolysis or renal failure throughout the duration of the studies. Conclusions Treatment with once-daily zasocitinib generally did not result in clinically meaningful laboratory changes in haematological, hepatic, renal or lipid parameters for up to 60 weeks."

Clinical • P3 data • Dermatology • Dyslipidemia • Immunology • Plaque Psoriasis • Psoriasis • Renal Disease • TYK2

Selective TYK2 Inhibition in Plaque Psoriasis: A Systematic Review of Deucravacitinib with Clinical Perspective (EADV 2026) - "In India, conventional systemic agents such as methotrexate, cyclosporine, and acitretin continue to be widely used; however, their long-term use is constrained by organ toxicity, laboratory monitoring burden, and tolerability issues...The phase 3 POETYK PSO-1 and PSO-2 trials demonstrated significantly greater efficacy of deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis, with higher PASI 75, PASI 90, and sPGA 0/1 response rates at Weeks 16 and 52...Its selective allosteric inhibition of TYK2, robust efficacy, durable long-term responses, and favorable safety profile distinguish it from conventional JAK inhibitors and other oral systemic therapies. In resource-constrained settings, deucravacitinib has the potential to bridge an important therapeutic gap between traditional systemic agents and biologics, although broader accessibility, cost-effectiveness, and real-world evidence will determine its future role in routine clinical practice."

Clinical • Review • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Venous Thromboembolism • IL12A • IL17A • IL23A • JAK1 • TNFA • TYK2

Once-daily oral zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile in moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) (EADV 2026) - P3 | "Materials and Methods Two phase 3 randomized, double-blinded, global, multicentre trials compared zasocitinib 30 mg once daily with placebo or apremilast 30 mg twice daily over 52 (LATITUDE-PsO-3001) or 60 weeks (LATITUDE-PsO-3002). The most frequently occurring adverse events (≥ 5%) observed with zasocitinib were upper respiratory tract infection, nasopharyngitis and acne. Conclusions Once-daily zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile across two pivotal phase 3 trials."

Clinical • P3 data • Acne Vulgaris • Dermatology • Immunology • Infectious Disease • Inflammation • Plaque Psoriasis • Psoriasis • Respiratory Diseases • TYK2

Real-world data assessing the efficacy and tolerability of deucravacitinib and apremilast: A retrospective, single-centre observational study (EADV 2026) - "These drugs are typically prescribed to patients after the failure or contraindication of topical treatments, UV therapy, and methotrexate. As the cohort size was insufficient to assess the long-term effectiveness and tolerability of deucravacitinib in routine clinical practice, further follow-up is required. Overall, this study supports the use of apremilast as an oral, systemic, non-biologic therapy for patients who are unsuitable or ineligible for biologic therapy."

Observational data • Real-world • Real-world evidence • Retrospective data • Immunology • Psoriasis • TYK2

Real-World Effectiveness, Drug Survival and Laboratory Changes in Patients with Plaque Psoriasis Treated with Apremilast (EADV 2026) - "Although only NLR showed a statistically significant reduction, several inflammatory indices demonstrated a numerical downward trend, suggesting a potential modulatory effect of apremilast on systemic inflammation. Metabolic parameters remained stable during follow-up, and early clinical response may be associated with improved treatment persistence."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Dyslipidemia • Immunology • Inflammation • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Systemic Inflammatory Response Syndrome • CRP

Genital psoriasis (EADV 2026) - "Topical alternatives, such as roflumilast, are also available. Biotherapies, particularly ixekizumab, have demonstrated significant efficacy, while apremilast appears promising despite still limited data...A comprehensive clinical examination is essential. The development of specific assessment tools and tailored treatment algorithms appears necessary, particularly to better integrate the impact on quality of life into management decisions."

Dermatology • Immunology • Psoriasis

Sustained Disease Control in Refractory Hailey-Hailey Disease with Low-Dose Naltrexone and Adjunctive CO₂ Laser Ablation (EADV 2026) - "Previous treatments included topical and systemic corticosteroids, dapsone, acitretin, methotrexate, ciclosporin, mycophenolate mofetil, azathioprine, apremilast, etanercept, rituximab, botulinum toxin injections and multiple topical anti-inflammatory and antiseptic regimens, resulting only in transient or insufficient clinical responses. In persistent intertriginous lesions, adjunctive CO₂ laser ablation may further contribute to durable local disease control. Sequential multimodal treatment approaches may therefore represent a promising therapeutic strategy in selected patients with severe refractory Hailey-Hailey disease."

Genetic Disorders • Immunology • Infectious Disease

Treatment sequencing and drug survival in pustulosis palmoplantaris: a real-world cohort study (EADV 2026) - "Among therapies with n≥5, the most frequently used were apremilast (n=52), acitretin (n=41), ciclosporin (n=33), guselkumab (n=28), methotrexate (n=27), dimethylfumarate (n=19), fumaric acid esters (n=17), deucravacitinib (n=16), ixekizumab (n=10), bimekizumab (n=8), alitretinoin (n=7), and ustekinumab (n=5)...Kaplan–Meier analyses include therapies with ≥5 treatment episodes. Biologics and targeted therapies demonstrate more sustained treatment persistence compared to conventional systemic therapies."

Clinical • Real-world • Real-world evidence • Immunology

From Psoriasis to Eczema: A Case of Changing Th1/Th2 Predominance (EADV 2026) - "Her initial presentation in 2016 involved enlarging itchy red spots in her arms and legs that did not resolve with oral diphenhydramine...She did not respond to triamcinolone 0.1% ointment, hydrocortisone 2.5% cream, clobetasol, or daily oral cetirizine...Over the following year, her disease remained refractory despite treatment with adalimumab 40mg, apremilast 30mg, methotrexate 10mg, clobetasol 0.05% cream, tacrolimus 0.1% ointment, mupirocin 2% ointment, fexofenadine and cetirizine...Secukinumab was discontinued, resulting in partial improvement. In late 2025, ustekinumab was initiated...The patient was initiated on hydrocortisone 2.5% ointment, hydroxyzine 25 mg, and pimecrolimus 1% cream and her symptoms improved. Conclusion This case demonstrates sequential shifting between psoriatic presentations following initiation of multiple biologic therapies. Clinically, this emphasizes the need for routine diagnostic reassessment in patients to best tailor biologic..."

Clinical • Atopic Dermatitis • Dermatology • Gastroesophageal Reflux Disease • Immunology • Musculoskeletal Pain • Pruritus • Psoriasis

Roflumilast for Ulcers in Behçet's disease: Case report and review (EADV 2026) - "Although apremilast is an established PDE4 inhibitor for oral ulcers in BD, roflumilast remains an off-label option with limited published evidence...After failure of doxycycline and topical treatment, oral roflumilast was initiated in January 2025 using gradual dose escalation from 250 mcg three times weekly to 500 mcg every 1–2 days as tolerated; azathioprine was discontinued and certolizumab was maintained...Table 1. Published cases and treatment protocols of roflumilast in BD."

Case report • Clinical • Review • Ankylosing Spondylitis • Axial Spondyloarthritis • Crohn's disease • Endometriosis • Gastroenterology • Gynecology • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Melanoma • Ocular Inflammation • Ophthalmology • Rare Diseases • Seronegative Spondyloarthropathies • Solid Tumor • Uveitis • Women's Health